Literature DB >> 8556486

Respiratory syncytial virus group-specific antibody response in nasopharyngeal secretions from infants and children after primary infection.

H Yamazaki1, H Tsutsumi, K Matsuda, K Nagai, P L Ogra, S Chiba.   

Abstract

Respiratory syncytial virus (RSV) group-specific immunoglobulin A (IgA) and IgG enzyme-linked immunosorbent assay antibody and neutralizing antibody responses were determined for nasopharyngeal secretions (NPS) from 27 infants and children (6 to 18 months of age) undergoing primary infection with RSV group A or B strain. IgA and IgG antibody responses against RSV envelope glycoproteins (fusion [F] and large [G] glycoprotein) in NPS were also analyzed. Most subjects examined developed moderate levels of NPS IgA and IgG antibodies and neutralizing antibody activity to both group A and B strains in convalescent phase; however, the levels of antibodies to homologous strains were significantly higher than to the heterologous strains. Patients infected with group A developed antibodies in both F and G glycoproteins of A2 strains (group A). Patients infected with group B developed levels of antibody activity to F glycoprotein of A2 strain similar to those of patients infected with group A. However, these subjects developed little or no antibody response to G glycoprotein of A2 strain. These data suggest that the IgA and IgG antibody responses to G glycoprotein in the respiratory tract are group specific. It is suggested that lack of antibody response to the G glycoprotein of the heterologous group in the respiratory tract may determine the outcome of reinfection with other RSV strains.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8556486      PMCID: PMC368291          DOI: 10.1128/cdli.1.4.469-472.1994

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  22 in total

1.  Two distinct subtypes of human respiratory syncytial virus.

Authors:  M A Mufson; C Orvell; B Rafnar; E Norrby
Journal:  J Gen Virol       Date:  1985-10       Impact factor: 3.891

2.  Three antigenic variant groups in human respiratory syncytial virus subgroup B isolated in Japan.

Authors:  K Nagai; H Tsutsumi; H Yamazaki; S Pattamadilok; S Chiba
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

3.  Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies.

Authors:  L J Anderson; J C Hierholzer; C Tsou; R M Hendry; B F Fernie; Y Stone; K McIntosh
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

4.  Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness.

Authors:  J Mills; J E Van Kirk; P F Wright; R M Chanock
Journal:  J Immunol       Date:  1971-07       Impact factor: 5.422

5.  Antigenic variation between human respiratory syncytial virus isolates.

Authors:  H B Gimenez; N Hardman; H M Keir; P Cash
Journal:  J Gen Virol       Date:  1986-05       Impact factor: 3.891

6.  Purification and characterization of GP90, one of the envelope glycoproteins of respiratory syncytial virus.

Authors:  E E Walsh; J J Schlesinger; M W Brandriss
Journal:  J Gen Virol       Date:  1984-04       Impact factor: 3.891

7.  Secretory antibody response to respiratory syncytial virus infection.

Authors:  T N Kaul; R C Welliver; D T Wong; R A Udwadia; K Riddlesberger; P L Ogra
Journal:  Am J Dis Child       Date:  1981-11

8.  The immunologic response to infection with respiratory syncytial virus in infants.

Authors:  K McIntosh; H B Masters; I Orr; R K Chao; R M Barkin
Journal:  J Infect Dis       Date:  1978-07       Impact factor: 5.226

9.  Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children.

Authors:  F W Henderson; A M Collier; W A Clyde; F W Denny
Journal:  N Engl J Med       Date:  1979-03-08       Impact factor: 91.245

10.  The use of gowns and masks to control respiratory illness in pediatric hospital personnel.

Authors:  D Murphy; J K Todd; R K Chao; I Orr; K McIntosh
Journal:  J Pediatr       Date:  1981-11       Impact factor: 4.406

View more
  3 in total

Review 1.  Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus.

Authors:  Matthew R Olson; Steven M Varga
Journal:  Expert Rev Vaccines       Date:  2008-10       Impact factor: 5.217

2.  Development of interleukin 6 and tumor necrosis factor alpha activity in nasopharyngeal secretions of infants and children during infection with respiratory syncytial virus.

Authors:  K Matsuda; H Tsutsumi; Y Okamoto; C Chiba
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

Review 3.  The Human Immune Response to Respiratory Syncytial Virus Infection.

Authors:  Clark D Russell; Stefan A Unger; Marc Walton; Jürgen Schwarze
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.